Fasting plasma glucose to avoid a full OGTT in the diagnosis of gestational diabetes  by Trujillo, J. et al.
Fasting plasma glucose to avoid a full OGTT in the
diagnosis of gestational diabetes
J. Trujillo a,*, A. Vigo a, A. Reichelt b, B.B. Duncan a, M.I. Schmidt a
aPost Graduate Studies Program in Epidemiology, School of Medicine, Rio Grande do Sul Federal University,
Rua Ramiro Barcelos 2600, sala 414, 90035-003, Porto Alegre, RS, Brazil
bHospital de Clı´nicas de Porto Alegre, Porto Alegre, Brazil
d i a b e t e s r e s e a r c h a n d c l i n i c a l p r a c t i c e 1 0 5 ( 2 0 1 4 ) 3 2 2 – 3 2 6
a r t i c l e i n f o
Article history:
Received 24 March 2014
Received in revised form
31 May 2014
Accepted 2 June 2014





a b s t r a c t
Aims: To evaluate the performance of fasting plasma glucose (FPG) in determining the need
for a full oral glucose tolerance test (OGTT) to diagnose gestational diabetes (GDM) by the
International Association of Diabetes and Pregnancy Study Groups (IADPSG) criteria.
Methods: A multicenter cohort study of 4926 pregnant women 20 years or older consecu-
tively enrolled in prenatal care clinics of the Brazilian National Health Service from 1991 to
1995. All women underwent a single 2 h 75 g OGTT by weeks 24–28 of pregnancy and were
followed to detect adverse pregnancy outcomes.
Results: A FPG cut-off value of 80 mg/dl indicated that only 38.7% of all women needed to
undergo a complete OGTT, while detecting 96.9% of all GDM cases. When the 85 mg/dl cut-
off was used, the corresponding percentages were 18.7% and 92.5%, respectively. The
fraction of women labeled with GDM who had adverse pregnancy outcomes was nearly
identical when using FPG strategies and universal full testing.
Conclusions: Using a FPG cut-off to diagnose GDM and to determine the need for post-load
OGTT measurements is a valid strategy to diagnose GDM by IADPSG criteria. This approach
may improve feasibility of applying IADPSG diagnostic criteria by reducing costs and
increasing convenience.
# 2014 Elsevier Ireland Ltd. All rights reserved.
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Gestational diabetes mellitus (GDM) has become an important
public health problem owing to its growing prevalence and its
association with adverse pregnancy outcomes and type 2
diabetes mellitus later in life. However, controversies on
screening and diagnostic strategies still remain.
In 2010, the International Association of Diabetes and
Pregnancy Study Groups (IADPSG) recommended applying a
diagnostic 2 h 75 g OGTT to all women reaching 24th to 28th
gestational weeks and not diagnosed as having overt diabetes* Corresponding author. Tel.: +55 51 33085347.
E-mail address: njtrujill@gmail.com (J. Trujillo).
http://dx.doi.org/10.1016/j.diabres.2014.06.001
0168-8227/# 2014 Elsevier Ireland Ltd. All rights reserved.or GDM earlier in the pregnancy [1]. This criterion has been
endorsed by the American Diabetes Association (ADA) and by
the World Health Organization (WHO) for the diagnosis of
gestational diabetes [2,3]. However, its poor cost-effectiveness
has limited its implementation [4], so that new strategies are
being considered to improve this setting.
In Brazil, a fasting plasma glucose (FPG) test has been
largely used as a part of a two-step screening approach, with
cut-offs between 85 mg/dl (4.7 mmol/l) and 90 mg/dl (5 mmol/
l) to define a positive screening test, and thus the need for a
diagnostic test (2 h 75 g OGTT) [5]. These cut-offs have been
evaluated against the 1999 WHO criteria and the previous ADA
Table 1 – Characteristics of the 4926 women participating
in the Brazilian Gestational Diabetes Study.
Clinical characteristics Mean (SD) or N (%)
Maternal age (years) 27.8 (5.4)
BMI at the enrolment (kg/m2) 26.0 (4.0)







<8 years 2159 (43.9)
8–11 years 2275 (46.3)






Family history of diabetes (%) 685 (14.8)
Cesarean delivery (%) 1624 (37.8)
Number of women for each characteristic varies slightly due to
missing values.
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against the IADPSG criteria [8,9]. Neither of those previous
studies evaluated the ability of such a strategy to identify
women who suffered adverse pregnancy outcomes during
follow-up. The Brazilian Study of Gestational Diabetes (Estudo
Brasileiro de Diabetes Gestacional, or EBDG) [10] an observa-
tional study which tested and followed a large number of
pregnant women during a period in which diagnosis of
gestational diabetes was not standardized and treatment for
those with lesser than diabetes hyperglycemia was uncom-
mon, offers a good opportunity for further evaluation.
The purpose of this study was to evaluate a strategy based
on a FPG cut-off to avoid the necessity of obtaining 1 h and 2 h
OGTT measurements in the diagnosis of GDM based on the
IADPSG criteria.
2. Materials and methods
Analyses were based on the EBDG, a cohort of 5564 pregnant
women consecutively enrolled at gestational weeks 20th–
28th, and receiving prenatal care in the National Health
Service in six state capitals of Brazil from May 1991 to August
1995 [10]. Ethics committees of each center approved the
study protocol, and all patients gave informed consent to
participate.
Eligibility criteria included having no history of diabetes
outside pregnancy and being 20 years or older. At enrolment,
all women answered a structured questionnaire and were
scheduled for a single 2 h 75 g anhydrous glucose OGTT
according to standardized WHO procedures (plasma glucose
was measured in FPG, after load in 1 h and 2 h) [11]. The blood
samples were collected in fluoride tubes and kept them at 48 C
until centrifugation, up to 2 h later. Plasma glucose was
measured by glucose oxidase method [12] in local laboratories
previously certified by the Study’s quality control committee.
External quality controls with three different glucose con-
centrations were used for certification and monitoring. A
coefficient of variation 5% at any point was a reason to
suspend glucose determinations.
Body mass index (BMI) was calculated as weight (kg)/height
(cm)2 based on anthropometric measures at enrolment
obtained in duplicate following a standard protocol. GDM
was defined according to the IADPSG diagnostic criteria, which
require only one abnormal value out of the three cut-off
points: fasting 92 mg/dl (5.1 mmol/l); 1 h 180 mg/dl
(10.0 mmol/l); or 2 h 153 mg/dl (8.5 mmol/l) [1].
Women were followed until delivery, data on outcomes
being collected from chart review using a structured protocol.
The composite adverse pregnancy outcome consisted of at
least one of the following three outcomes: large for gestational
age, preeclampsia or perinatal death. LGA was defined as a
birth weight at or above the gestational age-specific (by week)
90th percentile for the study sample, as previously described
[10]. Preeclampsia (or eclampsia) was defined as either chronic
or incident hypertension associated with either proteinuria or
convulsions after 20 weeks of gestation, in accordance with
the recommendations of the National High Blood Pressure
Education Program Working Group [13]. Perinatal deaths were
ascertained as a fetal loss weighting more than 1 kg or withestimated gestational age >28th weeks; or an early neonatal
death (up to 7 days).
Data were available for 4926 (90%) women, after excluding
566 women who did not perform the OGTT or had incomplete
values for the OGTT, 21 women reaching criteria for diabetes
(fasting plasma glucose level 126 mg/dl and/or 2 h plasma
glucose level 200 mg/dl), 2 women who received insulin
treatment, and 49 women with multiple pregnancies. Missing
values for the different outcomes led to slight variation in the
total sample size of specific analyses. Analyses of adverse
pregnancy outcomes, due to losses during follow-up, were
performed on data for 4160 women.
Data are described as absolute and relative frequencies (%)
for categorical variables, and as mean and standard deviation
(SD) for continuous ones. The performance of FPG in detecting
GDM as diagnosed by the IADPSG criteria and in predicting the
composite outcome of adverse pregnancy events was evalu-
ated using the area under the receiver operating characteristic
(ROC) curve (AUC). We calculated sensitivity, specificity, and
positive and negative predictive values for FPG threshold
values considered relevant as well as the percentage of
women with a positive result for each threshold [14]. We
employed the FPG which was part of the previously described
OGTT in all analyses. The software package Statistical
Analysis System (version 9.2; SAS Institute, Cary, NC) was
used for all analyses.
3. Results
Main characteristics of pregnant women enrolled in the EBDG
study are presented in Table 1. Means (SD) of plasma glucose
for samples obtained during the OGTT were 81.5 mg/dl
(4.5 mmol/l) for fasting, 121.2 mg/dl (6.7 mmol/l) for 1 h, and
103.2 mg/dl (5.7 mmol/l) for 2 h values. Prevalence of GDM was
Table 2 – Performance of differing fasting plasma glucose
(FPG) values for the detection of gestational diabetes
(GDM) based on IADPSGa criteria and a composite
measure of adverse pregnancy outcomes.
Performance
measures
Cut-off points of FPG
(mg/dl)
80 85 90 92
Positive test (%) 54.3 34.3 19.8 15.6
Se (%)
To detect GDM 96.9 92.5 88.3 86.8
To predict adverse
outcomes
60.2 41.5 26.1 19.7
Sp (%)
To detect GDM 55.0 78.4 95.1 100.0
To predict adverse
outcomes
46.3 66.5 81.0 85.0
PPV (%)
To detect GDM 32.0 48.3 79.8 100.0
To predict adverse
outcomes
19.0 20.6 22.4 21.5
NPV (%)
To detect GDM 98.8 97.9 97.4 97.2
To predict adverse
outcomes
84.7 84.4 84.0 83.5
Se, sensitivity; Sp, specificity; PPV, positive predictive value; NPV,
negative predictive value.
a International Association of Diabetes and Pregnancy Study
Groups.
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criteria. There were 767 (15.6%) women with FPG 92 mg/dl.
We ascertained 721 (17.3%) composite adverse pregnancy
outcomes, 481 (11.8%) LGA newborns, 113 (2.7%) perinatal
deaths and 149 (3.6%) cases of preeclampsia. The capacity of
FPG values to detect GDM defined by the IADPSG diagnostic
criteria evaluated by the AUC was 0.960 (95% CI 0.952–0.969).
However, the AUC for the capacity of FPG values to detect the
composite adverse pregnancy outcome was only 0.549 (95% CI
0.526–0.573). For comparison, the AUC for the fasting, 1 h and
2 h glycemic levels together in the detection of this composite
outcome was 0.582 (95% CI 0.559–0.604), and similarly for only
1 h and 2 h levels together (AUC = 0.581, 95% CI 0.558–0.604).
Percent of women with a positive test, sensitivity,
specificity, and positive and negative predictive values forTable 3 – Outcome of strategies using FPG to direct further test
IADPSGa criteria.
Strategy Initial FPG results 
Cut-off
(mg/dl)
Screen + GDM Need OGTT
N (%) N (%) N (%) 
FPG, then
1 h and 2 h
80 2675 54.3 767 15.6 1908 38.7




LGA, large for gestational age; OGTT, oral glucose tolerance test.
a International Association of Diabetes and Pregnancy Study Groups.various FPG cut-off points are presented in Table 2. Values
between 80 and 92 mg/dl classified 54.3–15.6% of the women as
having a positive test and were thus considered as potentially
relevant cut-off points. Sensitivity decreased and specificity
increased as FPG cut-off points were raised, being 96.9% and
55.0% for the cut-off point of 80 mg/dl and 86.8% and 100% for
the cut-off point of 92 mg/dl. The diagnostic properties of FPG
for the detection of the composite adverse pregnancy outcome
were less favorable. Sensitivities ranged from 60.2% to 19.7%,
consistent with the low AUC of FPG in the prediction of these
outcomes. Overall, the most relevant cut-offs appeared to be
80 and 85 mg/dl.
Table 3 evaluates different cut-offs for detecting GDM using
this approach of avoiding 1 h and 2 h measures based on the
FPG value when compared to universal full OGTT testing as
recommended by the IADPSG. When testing initially with just
a FPG, values 92 mg/dl label women as GDM. Cut-off values
within the range of 80 and 85 mg/dl would classify 38.7%–
18.7% of all women as needing post-load OGTT measure-
ments. The percent of all IADPSG GDM cases detected with this
approach was 96.9% when using the cut-off point of 80 mg/dl,
and 92.5% when using the cut-off point of 85 mg/dl. The
prevalence of detected GDM by the FPG strategy based on
these two cut-offs was 17.4% and 16.6%, respectively,
compared to 18% with the universal full OGTT.
The percent of LGA births and preeclampsia cases
predicted with this FPG strategy (sensitivity) was very similar
to that predicted by the universal OGTT. The 80 mg/dl cut-off
identified the same number of cases who were diagnosed as
having preeclampsia during the pregnancy as universal full
OGTT testing, and only 0.4% fewer cases of LGA births.
4. Discussion
Our findings indicate that FPG, when used not just as part of
the IADPSG diagnostic algorithm, but also as a means of
avoiding 1 h and 2 h post-load measures, was an excellent
strategy to classify pregnant women into three groups – those
already meeting the IADPSG criteria; those not yet meeting
them but at a sufficiently high risk so as to merit post-load
OGTT measures; and those at sufficiently low risk not to
require any further testing. This FPG strategy correctlying in the diagnosis of gestational diabetes (GDM) based on
OGTT Total GDM Pregnancy outcomes
 GDM LGA Preeclampsia
N (%) N (%) N (%) N (%)
 89 4.7 856 96.9 112 23.3 31 20.8
 50 5.4 817 92.5 105 21.8 30 20.1
 883 18.0 883 100.0 114 23.7 31 20.8
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full OGTT in well over half of all women. Further, the
probability of not having GDM given a FPG value below the
cut-offs of 80 mg/dl and 85 mg/dl was very high, around 98%.
Additionally, and importantly, the fraction of women who
would go on to have an adverse pregnancy outcome predicted
by this strategy was quite similar to that obtained with
universal OGTT testing. This latter finding, to our knowledge,
has not been previously reported.
Over the years, FPG has been widely applied as a screening
test for GDM, given its advantages of being less expensive,
more reproducible, well accepted and easier to administer
universally. Furthermore, properties of FPG here described are
very similar to those described for the traditionally adopted
50 g OGTT in recent reviews [15,16].
Based on the previous ADA GDM criteria, FPG values between
85 and 89 mg/dl (4.7–4.9 mmol/l) presented sensitivity of about
80% and specificity of about 70% [7,17]. Based on the 1999 WHO
GDM criteria, sensitivity and specificity were 69% and 68%,
respectively, for a FPG cut-off point of 85 mg/dl [6]. Since the
evaluations utilized FPG obtained from the same test which
diagnosed GDM, these figures overestimate the diagnostic
properties if a two-step process is to be used, particularly those
based on the previous ADA criteria, which employed a lower
value of FPG in GDM diagnosis than the 1999 WHO criteria. Of
note, a FPG performed in early pregnancy was not shown to be a
good predictor of GDM when detected later in pregnancy [18].
Few studies have been performed investigating FPG as a
means of orienting further testing when GDM is based on
IADPSG criteria. Agarwal et al. [8] found an AUC of 0.907 (95%
CI 0.899–0.914) for FPG as a test to direct further testing for the
detection of GDM. The authors recommended a cut-off point
of 4.4 mmol/l (80 mg/dl), which provided a sensitivity of 95.4%
and specificity of 32.0%. Another recent study also suggested
the cut-off value of 4.4 mmol/l, finding a sensitivity of 87.8%
and specificity of 45.8%, although the AUC found for FPG was
lower, 0.836 (95% CI 0.829–0.843) [9]. However, neither of these
studies evaluated the performance of FPG, when used for this
purpose, in predicting pregnancy outcomes, as we have done.
Even though maternal and fetal outcomes could have been
improved by treatment, it should be emphasized that our
study occurred in a time when lifestyle interventions were not
routinely recommended. Also, diagnostic cut-off values for
GDM were higher and not consensual and we excluded from
the analyses the few women who received insulin treatment.
A feasible FPG strategy would be as follows. A FPG 92 mg/
dl would label women as GDM. Cut-off points of FPG between
80 and 85 mg/dl could then be chosen to indicate the need for
1 h and 2 h post load testing for those with FPG <92 mg/dl,
according to resources available in specific settings. Using a
cut-off of 80 mg/dl, more than one-third of all women would
be classified as requiring the OGTT, in a process which detects
96.9% of IADPSG defined GDM cases. Using a cut-off of 85 mg/
dl, less than 20% of all women would require OGTT testing, in a
process which detects 92.5% of these GDM cases. The choice of
the threshold is dependent on the local priorities and the
resources available for GDM screening.
When to perform post-load testing in those for which the
FPG does not complete diagnostic classification merits
discussion. Ideally, it should be performed during the sameclinic visit. However, as has been noted [19], this is not always
possible. If the OGTT were performed on a subsequent visit,
the diagnostic criteria shown here will somewhat overesti-
mate reality, given that plasma glucose level varies from day to
day. We know of no evaluation of this short term variability in
pregnancy. However, it is not high in the general population
[20], and thus should not alter the diagnostic properties of the
criteria greatly.
The extrapolation of these results to other populations
merits discussion, given the wide variability in the percentage
of women diagnosed with GDM exclusively by FPG [21–23].
Although reasons for this variability are not clear, ethnicity
and varying rates of obesity may play a role [24]. Incomplete
fasting could be another reason. In this regard, our results are
more directly applicable to populations with a high fraction of
GDM women being diagnosed with FPG. However, studies
performed in settings with a lower fraction of GDM diagnosed
by FPG [8,9] also show excellent results for this strategy. When
incomplete fasting is likely, repeat testing of FPG for women
with an initial FPG 92 mg/dl is indicated. A possible
additional strategy, which would not require rapid laboratory
turnaround, is to test all women initially with a FPG and, on a
second visit, to repeat the FPG for confirmation when the
initial value was 92 mg/dl and to perform an OGTT when the
initial value was less than 92 mg/dl but above the cut-off point
of 80 (or 85) mg/dl.
An additional potential limitation of our study is the
possibility of selection bias due to missing information or
incomplete follow-up. However, the OGTT was performed in
over 90% of the women enrolled; outcomes were ascertained
for at least 74% of all enrolled women and for 80% of those who
underwent a 2 h 75 g OGTT.
In conclusion, a strategy in which FPG is used to detect
cases of GDM and to determine the extent of further testing
appears to be a valid approach to identify women with GDM by
IADPSG criteria. This strategy would improve the feasibility of
applying IADPSG diagnostic criteria by reducing costs and
improving the convenience of GDM detection in pregnancy.
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